| Literature DB >> 34359651 |
Vincenzo Di Nunno1, Enrico Franceschi1, Alicia Tosoni1, Lidia Gatto1, Raffaele Lodi2, Stefania Bartolini1, Alba Ariela Brandes1.
Abstract
Management of glioblastoma is a clinical challenge since very few systemic treatments have shown clinical efficacy in recurrent disease. Thanks to an increased knowledge of the biological and molecular mechanisms related to disease progression and growth, promising novel treatment strategies are emerging. The expanding availability of innovative compounds requires the design of a new generation of clinical trials, testing experimental compounds in a short time and tailoring the sample cohort based on molecular and clinical behaviors. In this review, we focused our attention on the assessment of promising novel treatment approaches, discussing novel trial design and possible future fields of development in this setting.Entities:
Keywords: GBM; glioblastoma; new trial design; newly diagnosed glioblastoma; recurrent glioblastoma
Year: 2021 PMID: 34359651 DOI: 10.3390/cancers13153750
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639